Physician profile
Lawrence Kogan
NPI 1659931368
$927.19
in general payments reported to CMS, 2019-2025
13 companies · $555 in 2025
The $555 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $122 · 2023: $125 · 2024: $125 · 2025: $555.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $806.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $805.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $417.93 | 2023-2025 | |
| Intercept Pharmaceuticals, INC. | $121.65 | 2019 | |
| Ardelyx, INC. | $77.15 | 2025 | Ibsrela |
| Janssen Biotech, INC. | $62.87 | 2025 | Tremfya |
| Madrigal Pharmaceuticals | $55.86 | 2025 | Rezdiffra |
| Aimmune Therapeutics, INC. | $41.42 | 2025 | Zenpep |
| Amgen INC. | $25.30 | 2025 | Uplizna |
| Gilead Sciences, INC. | $23.70 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $22.51 | 2025 | Dupixent |
| Genzyme Corporation | $21.82 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $21.44 | 2025 | Relistor |
| Intra-Sana Laboratories | $18.17 | 2025 | Reltone 200 Mg, Glycate, Reltone 400 Mg |
| Novo Nordisk INC | $17.37 | 2025 | Wegovy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lawrence Kogan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.